Login to Your Account

Novabiotics, Taro Ink Alliance For Phase IIb-Ready Antifungal

Wednesday, September 4, 2013
LONDON – Novabiotics Ltd. rejected a new round of private funding in favor of an exclusive licensing deal with Taro Pharmaceuticals North America Inc., for the co-development of its first-in-class antifungal peptide Novexatin, which is about to enter Phase IIb development in the treatment of nail infection onychomycosis.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription